Neoadjuvant Phase II Study Of Everolimus Plus Cisplatin In Triple Negative Breast Cancer Patients With Residual Disease After Standard Chemotherapy
Phase of Trial: Phase II
Latest Information Update: 24 Oct 2016
At a glance
- Drugs Everolimus (Primary) ; Cisplatin
- Indications Breast cancer
- Focus Therapeutic Use
- Acronyms NECTAR
- 07 Oct 2015 Planned End Date changed from 1 Aug 2016 to 1 Aug 2017 as reported by ClinicalTrials.gov record.
- 07 Oct 2015 Planned primary completion date changed from 1 Aug 2015 to 1 Aug 2017 as reported by ClinicalTrials.gov record.
- 03 Sep 2013 New trial record